ImmunoGen, Inc. Announces Clinical and Preclinical Data Presentations at Upcoming 56th ASH Annual Meeting and Exposition
25 November 2014 - 7:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced the data presentations
on Company and partner experimental therapies to be made at the
upcoming American Society of Hematology (ASH) annual meeting to be
held December 6-9, 2014 in San Francisco, CA.
“We believe the new data being reported with our IMGN529 and
IMGN779 ADCs will help convey why we believe these have the
potential to make important differences for patients with certain
B-cell malignancies and acute myeloid leukemia, respectively,”
commented Daniel Junius, President and CEO. “We expect to advance
IMGN529 into disease-specific testing in the first half of 2015 and
IMGN779 into initial clinical testing in the second half of 2015.
Our partners continue to make progress as well, with new clinical
data to be presented with Biotest’s indatuximab ravtansine, or
BT-062, ADC and Sanofi’s SAR650984 CD38-targeting antibody."
Presentations on ImmunoGen Wholly Owned ADCs
Title: "A Phase I Study of IMGN529, an Antibody-Drug Conjugate
(ADC) Targeting CD37, in Adult Patients with Relapsed or Refractory
B-Cell Non-Hodgkin’s Lymphoma (NHL)."
- Poster session (PS) #624: Saturday,
Dec. 6, 5:30-7:30 pm PST. Abstract #1760.
Title: "Preclinical Mechanistic Studies Investigating Neutrophil
and Lymphoid Cell Depletion By IMGN529, a CD37-Targeting
Antibody-Drug Conjugate (ADC).”
- PS #625: Sunday, Dec. 7, 6:00-8:00 pm
PST. Abstract #3119.
Title: "The Antibody-Drug Conjugate (ADC) IMGN779 Is Highly
Active in Vitro and in Vivo Against Acute Myeloid Leukemia (AML)
with FLT3-ITD Mutations."
- PS #616: Sunday, Dec. 7, 6:00-8:00 pm
PST. Abstract #2321.
Presentations on Partner Compounds
Title: "SAR650984 (SAR) Directly Promotes Homotypic
Adhesion-Related Multiple Myeloma (MM) Cell Death and SAR-Induced
Anti-MM Activities Are Enhanced By Pomalidomide, More Potently Than
Lenalidomide.”
- PS #653: Saturday, Dec. 6, 5:30-7:30 pm
PST. Abstract #2124.
Title: "KIR and HLA Genotypes Influence Clinical Outcome in
Multiple Myeloma Patients Treated with SAR650984 (Anti-CD38) in
Combination with Lenalidomide and Dexamethasone.”
- PS #653: Saturday, Dec. 6, 5:30-7:30 pm
PST. Abstract #2126.
Title: "A Phase Ib Dose Escalation Trial of SAR650984
(Anti-CD-38 mAb) in Combination with Lenalidomide and Dexamethasone
in Relapsed/Refractory Multiple Myeloma.”
- Presentation
time: Sunday, Dec. 7, at 1:00 pm PST. Abstract #83.
Title: "Indatuximab Ravtansine (BT062) in Combination with
Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed
and/or Refractory Multiple Myeloma: Clinical Activity in Patients
Already Exposed to Lenalidomide and Bortezomib.”
- PS #653: Monday, Dec. 8, 6:00-8:00 pm
PST. Abstract #4736.
Additional information can be found at www.hematology.org,
including the abstracts.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells; the
Company has also developed antibodies with anticancer activity of
their own. The first product with ImmunoGen’s ADC technology is
Roche’s Kadcyla®. ImmunoGen has three wholly owned product
candidates in clinical testing with additional compounds in
clinical testing through the Company’s partnerships with Amgen,
Bayer HealthCare, Biotest and Sanofi. More information about
ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
This press release includes forward-looking statements. For
these statements, ImmunoGen claims the protection of the safe
harbor for forward-looking statements provided by the Private
Securities Litigation Reform Act of 1995. It should be noted that
there are risks and uncertainties related to the development of
novel anticancer products, including IMGN529, IMGN779, BT-062, and
SAR650984, including risks related to preclinical and clinical
studies, their timings and results. A review of these risks can be
found in ImmunoGen’s Annual Report on Form 10-K for the fiscal year
ended June 30, 2014 and other reports filed with the Securities and
Exchange Commission.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Jul 2023 to Jul 2024